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Abstract
Introduction—This systematic review examines the excess cost of chronic conditions on the 
economic burden of cancer survivorship among adults in the US.
Areas covered—Twelve published studies were identified. Although studies varied substantially 
in populations, comorbidities examined, methods, and types of cost reported, costs for cancer 
survivors with comorbidities generally increased with greater numbers of comorbidities or an 
increase in comorbidity index score. Survivors with comorbidities incurred significantly more in 
total medical costs, out-of-pocket costs, and costs by service type compared to cancer survivors 
without additional comorbidities.
Expert commentary—Cancer survivors with comorbidities bear significant excess out-of-
pocket costs and their care is also more expensive to the healthcare system. On-going evaluation of 
different payment models, care coordination, and disease management programs for cancer 
survivors with comorbidities will be important in monitoring impact on healthcare costs.
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1. Introduction
Cancer survivors, both those undergoing active treatment or who have lived with the 
diagnosis long-term, are a steadily growing segment of the US population [1]. There are 
approximately 15.5 million cancer survivors in the United States, with numbers projected to 
exceed 20 million by 2026 [1,2]. Older age and other behavioral factors, such as tobacco use 
and lack of physical activity, are concurrent risk factors for cancer as well as developing 
other chronic conditions (e.g. obesity, diabetes, chronic obstructive pulmonary disease) [3]. 
Cooccurrence of these conditions (or multiple chronic conditions [MCCs] or multi-
morbidity) is highly-prevalent among cancer survivors, occurring in about 7 out of 10 
survivors [4–6]. MCCs among cancer survivors [4,7,8] can complicate health-care delivery 
(i.e. cancer treatment) and create practical concerns about survivorship care [9]. The 
presence of MCCs may also increase health-care costs for patients and the health-care 
system more broadly.
The economic burden of cancer survivorship in the United States is substantial [10–13]. 
Cancer survivors continue to have unique medical and psychosocial health-care needs 
related to their cancer diagnosis that impact health-care costs long after diagnosis [11]. Prior 
studies have demonstrated that cancer survivors incur, on average, $3000–4000 (US $2011 
dollars) in added medical costs compared to individuals without a cancer history [13]. 
Additionally, survivors have been shown to have more health concerns posttreatment than 
age- and sex-matched controls [14], and are also more likely to have hospitalizations, 
emergency room visits, ambulatory surgeries, and office visits than individuals without a 
cancer history [15,16]. Cancer survivors also face varying degrees of challenges with 
coexisting conditions, unmet psychological needs, and financial hardship throughout 
survivorship [11,17]. In light of recent transformations in the health-care system [18,19] and 
as more people survive to older ages with MCCs, it is critical to examine the excess burden 
that chronic conditions impose on survivors’ medical-care costs as well as other aspects of 
economic burden, including productivity losses due to employment disability, missed work 
days, and inability to participate in usual activities.
The purpose of this study was to systematically review and synthesize findings from the 
published literature on the economic burden of chronic conditions among cancer survivors in 
the United States. Our findings will inform understanding of the potential benefits of 
effective prevention and early detection efforts and chronic disease management efforts for 
cancer survivors. This review will also identify research gaps and areas for future health 
intervention efforts.
2. Methods
2.1. Search strategy and study selection
Published papers examining the excess cost of chronic conditions among cancer survivors 
were identified from the following electronic databases: PubMed, Web of Science Core 
Collection, and EconLit via EBSCOHost. The searches were limited to English language 
studies published from January 2000 through December 2015. Search terms were identified 
to retrieve articles addressing the three main concepts in the research question: (1) cancer 
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survivors (i.e. any person who has ever been diagnosed with cancer) [1], (2) comorbidities/
multi-morbidity/(multiple) chronic conditions, and (3) economic burden, including medical-
care costs and productivity losses. Specific comorbidity and chronic condition terms were 
derived from the most prevalent conditions [3] and key relevant articles [20,21]. Terms to 
identify health-care costs were adapted from a summary of health-care cost data sources 
[22]. The exact search strategy used in each of the electronic databases is reported in 
Appendix. Because electronic search strategies may be incomplete [23], we also manually 
searched the reference lists from selected articles to ensure a comprehensive review of the 
literature.
All references were uploaded to Covidence Systematic Review software (https://
www.covidence.org), a web-based tool designed to facilitate and track each step of the 
abstraction and review process. Two reviewers (SHR and GPG) conducted dual review of the 
titles and abstracts. Articles were excluded if the abstract did not contain some indication of 
‘cost,’ ‘comorbidities,’ or ‘cancer’; or the study population consisted only of cancer 
survivors outside the United States. A full-text review of all potentially relevant articles to 
further assess eligibility was then conducted. Study inclusion criteria entailed the reporting 
of estimates of costs (medical expenditures, lost productivity, or financial burden) related to 
chronic conditions among adult cancer survivors. Studies that analyzed the impact of 
comorbidities only on the cost of a specific procedure (i.e. surgery) or medication among 
cancer survivors were excluded. We also excluded gray literature (dissertations, government 
reports, issue briefs), editorials, essays, reviews/systematic reviews, and cost-effectiveness 
studies. Any discrepancies about eligibility were resolved through discussion and consensus 
between the two reviewers. Our search identified 2,317 studies of which 2,268 were 
excluded based on abstract review, leaving 49 articles for full-text review. Of the 49 articles, 
37 did not include cost information among cancer survivors by comorbidity, and 12 met all 
inclusion criteria (Figure 1) [21,24–34]. No additional articles were identified through 
manual reference list search.
2.2. Data abstraction
We abstracted detailed information on the study characteristics, cancer survivor population, 
comorbidities reported, and type of cost estimates included. The study characteristics 
included data source(s), method of identifying the cancer survivor study population (registry, 
claims, self-report), data year(s), and geographic setting (single state, multistate, national). 
For each study, the cancer survivor population was described by size (number of survivors), 
age, and type of cancer. The additional costs due to the presence of comorbidities were 
quantified both overall, and by service type (inpatient, outpatient, and prescription drugs) 
and source of payment (out-of-pocket expenditures), when available. Comorbidity cost 
estimates were abstracted separately for each individual condition and for the presence of 
MCCs. We did not adjust costs to a single reference year because of the heterogeneity in 
patient populations, care settings, measures, treatment costs, and other differences in 
methodology that would prohibit a meaningful interpretation of estimates [35]. Additionally, 
the studies were conducted across periods with varying treatment patterns and health-care 
payment models. Instead, we report all costs as presented in the underlying studies. This 
heterogeneity across studies also prohibited a quantitative synthesis of cost estimates.
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3. Results
3.1. Study characteristics
Table 1 provides an overview of the 12 studies included in the systematic review. While each 
study included information on medical expenditures due to comorbidities, none provided 
estimates of lost productivity. To estimate medical expenditures, the studies used a variety of 
data sources, including Surveillance, Epidemiology, End Result (SEER)-Medicare linked 
data (five studies), the Medical Expenditure Panel Survey (MEPS) (four studies), Medicaid 
(two studies), and the Medicare Current Beneficiary Survey (one study). The majority (10 
studies) utilized national or nationally representative data and represented different cancers 
including thyroid, oral cavity/pharyngeal, renal cell carcinoma, head/neck cancers, ovarian, 
colon, and ‘all cancer’ sites. Most articles (10 of 12 studies) reported an aggregated index 
for comorbidities (e.g. Charlson Comorbidity Index, Washington University Head and Neck 
Cancer Comorbidity Index) and 2 articles examined both individual chronic conditions and 
multiple conditions as a count. Because claims-based indexes typically use information 
about conditions prior to cancer diagnosis, some studies using Medicare claims data restrict 
their samples to patients ages 66 and older (1 year after age-based Medicare eligibility). All 
articles were published between 2003 and 2015.
3.2. Excess medical costs per person associated with specific chronic conditions among 
cancer survivors
Four studies provided estimates of the additional medical costs attributable to individual 
chronic conditions (Table 2) [21,29,31,34]. Among cancer survivors enrolled in Medicaid in 
three states (Georgia, Maine, or Illinois), the additional total cost of care over a 6-month 
period ranged from $3418 to $4385 for cardiac conditions; $5040 to $8155 for respiratory 
conditions; and $7483 to $7714 for diabetes (all US$ 2003) [21]. Among elderly renal cell 
carcinoma cancer survivors, the additional 1-year Medicare costs of care attributed to 
hyperlipidemia and anemia were $2745 and $2167 (US$ 2005), respectively [31]. Within a 
nationally representative sample, the additional annual cost of psychosocial distress was 
estimated to be $4431 (US$ 2010) [29] and $6310 (US$ 2009) for depression [34] among 
cancer survivors. Meanwhile, among cancer survivors enrolled in Medicaid in Georgia, 
Maine, or Illinois [21], the estimated additional costs of mental health disorders (including 
schizophrenic disorders, episodic mood disorders, delusional disorders, anxiety/personality 
disorders, and depressive disorders) was $8004 to $11,009 over a 6-month period (US
$ 2003) [21].
Two studies provided estimates of the additional medical costs associated with individual 
chronic conditions by service type [21,34]. Hospital costs accounted for the largest 
additional per person 6-month medical costs associated with cardiac conditions, respiratory 
conditions, diabetes, and mental health [21]. Additional prescription drug costs per person 
were highest for survivors with diabetes ($1011, US$ 2003) [21]. Mental health had the 
highest hospital ($6883), long-term care ($2214), and ambulatory care costs ($1198) 
compared to other conditions (in US$ 2003) [21]. The added 1-year costs per cancer 
survivor with depression were highest in the hospital and ambulatory care setting [34].
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3.3. Excess total medical costs per person associated with MCCs among cancer survivors
Regardless of the specific comorbid condition(s), the average cost of care for patients with 
chronic comorbidities increased with greater numbers of comorbidities or with an increase 
in the comorbidity index score (Table 3). Having one additional comorbidity compared to 
none was associated with increased annual costs of $2762 among colon cancer survivors 
with Medicare/Medicaid in Michigan (US$ 2001) [33], and increased 6-month costs of 
$4584 among cancer survivors of all sites in Medicaid patients in Georgia, Maine, or Illinois 
(US$ 2003) [21]. For ovarian cancer patients, the 7-month cost of care (US$ 2010 dollars) 
for having one comorbidity (compared to none) was $1793 for stage IIIC patients and $5625 
for stage IV patients [28]. As the number of comorbidities increased, the cost attributed to 
comorbidities increased substantially. For example, costs were $13,369 and $25,739 higher 
among cancer survivors of all sites in Medicaid in Georgia, Maine, or Illinois with 2 
comorbidities and ≥3 comorbidities, respectively, compared to cancer survivors with no 
additional comorbidities (US$ 2003) [21]. Similar trends were found across several studies 
for thyroid, oral cavity, pharyngeal, colon, and ovarian cancer survivors [25,28,30,31,33].
The excess cost of comorbidities was about twofold higher among those with three to four 
comorbidities compared to survivors with two comorbidities, when examined by service 
type (Table 4). Hospital costs, for example were $18,211 for cancer patients with 3–4 
comorbidities compared to $9891 among patients with 2 comorbidities (US$ 2003) [21].
Two studies examined the additional out-of-pocket expenditures attributed to comorbidities 
and found that annual out-of-pocket expenditures also increased as the number of 
comorbidities increased (Table 5) [24,27]. Among cancer survivors in Medicare, out-of-
pocket costs were $2133 and $3275 higher (in US$ 2007 dollars) among individuals with 5–
8 comorbidities and ≥9 comorbidities, respectively, compared to those with no additional 
comorbidities [27]. Among a nationally representative sample of cancer survivors, out-of-
pocket costs were $879 (US$ 2008) higher among those with other comorbidities compared 
to cancer survivors with no additional comorbidities [24] (Table 5).
4. Discussion
In this study, we conducted a systematic review of studies published within the last 15 years 
on the economic burden of chronic conditions among cancer survivors. Despite the 
increasing prevalence of cancer survivorship and chronic conditions, few studies have 
addressed this important topic. As expected, the studies varied on the patient populations 
included, data collection methods used, comorbidities considered, and costing approaches. 
Although the differences between studies complicate any direct comparison and quantitative 
synthesis across studies [35], our findings do highlight some, key commonalities. First, 
within each study, the additional cost of care for cancer survivors with chronic conditions 
increased with greater numbers of conditions or with an increase in the comorbidity index 
score, regardless of the specific comorbid condition(s). Mental health disorders [21], 
psychological distress [29], and depression [34] were among those associated with 
considerably greater total health-care costs by all service types. Second, within studies 
examining out-of-pocket medical costs [24,27], survivors with the highest number of 
comorbidities paid considerably more out-of-pocket (up to $3275, US$ 2007) compared to 
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cancer survivors without comorbidities, even after controlling for type of insurance. Thus, 
our findings highlight the potential economic gains that could be realized by preventing or 
reducing chronic conditions among cancer survivors. They also underscore the need for 
continued efforts in evaluating the economic burden of cancer survivorship and the financial 
hardship faced by cancer survivors. Improved understanding of the relative importance of 
different aspects of economic burden at the societal, health system, employer, and patient 
and family levels will be important for future research.
Our findings are salient for adult cancer survivors with greater number of comorbidities, 
whom tend to incur excess financial burden throughout survivorship and will likely continue 
to experience greater burden as the cost of cancer therapies increase [11,36]. Along with 
rising health-care costs [37], the affordability of care is also a major concern as the onus of 
medical costs have gradually shifted toward the patient with increasing deductibles, 
copayments, and use of coinsurance [11,36]. Even with health insurance, cancer survivors 
and particularly those with a higher number of comorbidities will be vulnerable to the 
deductibles and out-of-pocket costs. For example, the maximum out-of-pocket limit for a 
family plan is $13,700 (Health Insurance Marketplace in 2016), or the equivalent of 
approximately one-fifth of the median family income for a family of four in the United 
States (according to the US Census Bureau, American Community Survey 2014). In 
addition, given the increasing prevalence of material and psychological financial hardship 
(e.g. debt, bankruptcy, and worries about medical bills) associated with cancer [11,36], 
improved education, targeted interventions, and/or coordinated disease management efforts 
continue to be critical. As oncologists are increasingly discussing the financial consequences 
of treatment options with their patients as a component of delivering high-quality care 
[38,39], greater awareness, and educational/social support tools are useful to help address 
the economic burden among survivors with MCCs.
4.1. Addressing comorbidities in cancer survivorship
Persons with MCCs have been in the spotlight as a priority population, particularly in the 
past two decades [40,41]. This renewed attention coincides with the recognition that more 
people are living with chronic conditions [3], surviving cancers long-term [1], and that the 
proportion of individuals with both cancer and MCCs is sizable and growing. These 
concerns, coupled with the shifting focus of the health-care system toward delivering 
person-centered, team-based, coordinated health care [40], creates a need to consider 
different, innovative models of health-care delivery for this subgroup. As the projected cost 
of cancer care reaches an estimated $160 billion in 2020 [2], identifying ways of ensuring 
access to continued follow-up care and reducing unnecessary and avoidable health-care 
utilization through effective chronic disease management and coordinated efforts is 
important.
For example, patient-centered medical homes (PCMH) have emerged as one model of 
health-care delivery that may be well suited for persons with complex, comorbid conditions. 
Specifically, the ‘COME HOME Program’ [42] (http://www.comehomeprogram.com/
index.php/come-home-practices/), an oncology PCMH model conducted within seven 
community oncology practices in the United States, actively integrates infrastructure-, 
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clinical-, and payment-systems changes to deliver better patient-centered, coordinated, 
comprehensive care [42]. Preliminary evaluation of the program showed a reduction in 
unnecessary emergency room visits and hospitalizations, improved patient satisfaction, and 
projected Medicare savings of $4178 per member per year, though independent evaluation 
results have yet to be published. Other payment models, such as the Oncology Care Model 
(OCM) (https://innovation.cms.gov/initiatives/oncology-care/) for cancer patients receiving 
chemotherapy, focus on care coordination, improving clinic access, and providing guideline-
consistent care. Implementation of the 5-year OCM began on July 1, 2016; however, as it 
progresses, evaluation of outcomes of cancer patients with multiple comorbidities will be 
important.
As the spending associated with chronic disease/comorbidities among cancer survivors 
increases for both the patient-(out-of-pocket) and health-care systems [43], it will 
increasingly be necessary to identify novel programs and implement proven, scalable ones 
for survivors with MCCs. ‘Fostering health care and public health system changes’ and 
‘maximizing the use of proven self-care management and other services’ to improve the 
health of individuals with MCCs are among the US Department of Health and Human 
Services (DHHS) strategic vision for Individuals with MCCs [44]. Per this DHHS strategic 
vision, there is a call to ‘facilitate research to fill knowledge gaps about, and interventions 
and systems to benefits, individuals with multiple chronic conditions.’ [44] Our analysis 
identified several research gaps and areas for future research, as a starting point for these 
efforts.
Currently, comprehensive, population-based, longitudinal data on cancer patients and 
comorbidities is limited. These data are critical for understanding the timing of the onset of 
chronic conditions and cancer diagnosis. The published literature addressing cancer 
survivors with multiple comorbidities mainly included two data sources, SEER-Medicare 
and the MEPS, both of which have inherent limitations in generalizability and 
representativeness of the full cancer burden within the United States. The linked SEER-
Medicare data only include information about Medicare payments for covered services, and 
do not include detailed information about out-of-pocket spending or other payers or any 
information about services that are not covered by the Medicare program. Medicare 
payments have been estimated to be about 60% of total spending [45]. In addition, these data 
are limited to Medicare beneficiaries, the majority of whom are aged ≥65 years. As such, 
estimates provided from these studies likely underestimate the impact of chronic conditions 
on cancer survivorship. Only four studies included in the systematic review represent 
younger cancer survivor populations under age 65 years, many of whom may be less likely 
to have MCCs but also may experience greater out-of-pocket burden and costs associated 
with survivorship compared to individuals their age without a cancer history. Furthermore, 
SEER registries capture only about 28% of the US population and over-represent urban area 
and individuals with higher income [46].
The second commonly used data set, MEPS, is a nationally representative household survey 
of health-care utilization and expenditures; while it is one of the most detailed data sources 
available for estimating medical expenditures and out-of-pocket costs, it is not without 
limitations. The sample is only inclusive of the non-institutionalized, civilian, adult US 
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population and these data rely on household-reporting, including the identification of cancer 
survivors, which introduces a potential for reporting bias [47]. The cancer diagnosis question 
in the MEPS refers to cancer or a malignancy of any kind, which may result in identifying 
those with pre-invasive disease as cancer survivors. Additionally, as others have noted, 
population-based household surveys are less likely to identify individuals with rare and 
short-survival, high-cost cancers [48,49]. Analyses using MEPS data also were unable to 
examine costs associated with terminal care, which are arguably among the most costly 
patients per capita and the data were also unable to examine the burden by cancer site given 
inadequate sample size [50]. To the extent that this is the case, the impact of cancer 
survivorship on out-of-pocket burden would be underestimated in the identified studies.
4.2. Future research
This systematic review of the literature identified several gaps that warrant further 
exploration. First, there were several common chronic conditions in which the economic 
burden was not estimated among cancer survivors (e.g. heart conditions, chronic obstructive 
pulmonary disease, asthma, mental and trauma-related disorders [20]). For example, while 
four studies reported on specific chronic conditions, only two of those studies itemized the 
costs associated with the most prevalent and costly chronic conditions [3,20] outside of 
mental health conditions. No studies specifically reported on the excess cost of trauma-
related disorders and arthritis, two of the top five most costly conditions, among adults 
cancer survivors [20]. Second, our systematic review identified no published studies that 
quantified the economic burden of lost productivity resulting from comorbidities among 
cancer survivors. Given that prior studies have shown chronic conditions to be associated 
with increased lost productivity among cancer survivors [21,51], this is a key area for further 
research. Third, only two studies reported on the added out-of-pocket costs that cancer 
survivors with comorbidities incur over those without comorbidities. Given the evidence that 
cancer survivors experience financial hardship, debt, and bankruptcy [11,36], more research 
is needed in this area to further assess the impact of rising out-of-pocket health-care costs 
among cancer survivors with additional chronic conditions. This work will be especially 
important among the uninsured and previously uninsured, who may face additional 
challenges with care coordination. Fourth, there was substantial variation across data 
sources, as previously noted [52], and by cancer types. Very few studies were able to stratify 
cost by cancer sites. This highlights the importance of conducting studies assessing 
economic burden using other data sources, such as commercial claims data. Lastly, while we 
only examined the excess costs from additional numbers of comorbidities in this systematic 
review, and not the impact of the magnitude or severity of comorbidities, we expect that the 
added cost would significantly increase with greater severity of chronic conditions. In this 
respect, future cost analyses are needed to examine the economic impact of severity and 
longitudinal coexistence of chronic conditions. Better documentation of the timing of 
chronic condition onset in relation to cancer diagnoses would allow better use of estimates in 
cost-effectiveness analyses of cancer treatment.
4.3. Limitations
Our systematic review of the published literature has some limitations. Because of the 
heterogeneity across studies, there were significant challenges to synthesizing the costs of 
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chronic conditions among cancer survivors based on the data from the underlying studies. 
Many of the challenges that others have noted [35], including the omission of cost 
adjustment years, inadequate explanation of methodology, and concerns about sample 
selection and representativeness, also pertained to this review. Furthermore, though we used 
several large databases (PubMed/MEDLINE, Web of Science Core Collection, and EconLit 
via EBSCOHost) devoted to health and economic literature/publications and also conducted 
a comprehensive review of the reference lists for additional studies according to best 
practices for systematic reviews, it is still possible that we may have still missed some 
studies for inclusion based on our search strategy.
4.4. Conclusion
In summary, our review of the published literature found that caring for cancer survivors 
with greater numbers of comorbidities cost more to the health-care system, accounting for 
greater health-care spending, including excess out-of-pocket costs compared to cancer 
survivors without chronic conditions. In this review, we observed several areas for future 
research that may aid in efforts to identify and implement chronic disease prevention, care 
coordination, and disease management programs for cancer survivors with comorbidities 
may help to mitigate these costs.
5. Expert commentary & 5-year view
‘The good physician treats the disease; the great physician treats the patient who 
has the disease.’
(William Osler, 19th century physician-scientist)
Some of the greatest challenges in the current health-care system may be in providing high-
quality evidence-based care to medically complex patients, including cancer survivors with 
MCCs. These challenges arise, in part, from the limited research not only on cancer 
survivors and those with coexisting chronic conditions, but also the combination of 
individuals with both cancer and multiple (coexisting) chronic conditions. The latter 
subpopulation, in particular, has largely been understudied to date given the clinical 
heterogeneity and complexity of conditions involved [41] and lack of successful models on 
how to effectively and efficiently deliver comprehensive and coordinated care for these 
individuals. With the US population aging rapidly, the proportion of cancer survivors 
growing, and the number of adults with chronic conditions increasing at about 1% per year 
[45], greater focus on delivering appropriate and high-quality, patient-centered care will be 
important for this population.
Cost of care in this subpopulation equally deserves attention. Given the substantial economic 
burden of caring for cancer survivors with MCCs and significant gaps in the literature, 
further research that enables a more granular examination of costs by different combinations 
of comorbidities, cancers, and measures of economic burden (i.e. lost productivity, years of 
potential life lost, quality-adjusted and disability-adjusted life years) are needed. 
Importantly, given that all of the studies in our systematic review were conducted using data 
prior to the introduction and full implementation of the Affordable Care Act (ACA), similar 
economic studies and those that include longer term trends of economic burden among 
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cancer survivors with MCCs post-ACA will be needed, as more people obtain affordable 
coverage under insurance plans offered through the Health Insurance Marketplace or 
Medicaid and subsequently access the health-care system. To these ends, attention to the 
impact of other provisions of the ACA – like the granting of coverage despite preexisting 
chronic conditions, prohibiting of annual and lifetime coverage limitations, and the 
expansion of Medicaid coverage in some states – may also be particularly relevant among 
cancer survivors with severe and multiple chronic conditions.
Approximately 40% of Americans are expected to develop cancer in their lifetime [53]. And 
more than 70% of US adults aged ≥65 years will have two or more chronic conditions [45]. 
If recent trends continue, cancer care spending will continue to accelerate due to the high 
cost of new therapies and the growing population of cancer patients at need of treatment and 
follow-up care [38]. Engaging and understanding viewpoints of the patients, providers, 
industry, and payers for how rising cancer costs can impact the system at each level will be 
important [38].
Over the next 5- to 10 years, the economic burden of medical care, particularly among the 
sickest patients (with cancer and/or severe or MCCs) may expand as a result of underlying 
demographics and developments of novel treatments as well as changes in the health-care 
system with the ACA [54]. While the care of cancer survivors may consider costs and 
affordability both to the individual and health-care system, it should not be at the expense of 
continuing to offer high-quality, patient-centered care to each individual. Greater efforts 
around patient education, disease management, and communication (among the ‘triad’ of 
decision-makers: patient, family/caregiver, physician [55]) could help to ensure that the 
patient voice, needs, and preferences are incorporated in the health-care decision-making 
process.
On-going research and evaluation efforts around patient-centered outcomes research 
initiatives, personalized (or precision) medicine Initiatives and value-based payment models 
such as the OCM and ‘COME HOME’ Program are necessary for progress to be made in 
providing high-quality, patient-centered care, while considering costs. Furthermore, most 
cancer survivors with severe chronic diseases will likely have an on-going need to ascertain 
symptoms for periodic changes and adjustments in medications, accordingly. Though big 
data and rapid learning health-care systems are still nascent in its uses, having the ability to 
link more robust information sources for diagnostic, medical, and treatment-related 
information with patient-reported outcomes will be likely be a promising resource in 
improving patient care and providing evidence for researchers how to optimize treatment 
delivery and effectiveness. Social and health systems policies continue to be necessary to 
help make these efforts sustainable and effective, long-term.
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Web of Science
TOPIC: (Neoplasm* OR Cancer*) AND TOPIC: (Chronic Disease* OR Chronic Condition* 
OR Chronic Illness* OR Chronically Ill OR Comorbid* OR Co morbid* OR Multimorbid* 
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Disorder* OR Depression OR Bipolar OR Anxiety Disorder* OR Stress OR Distress OR 
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Hypertension* OR Hyperlipidemia* OR High Blood Cholesterol OR Arthritis OR Diabetes 
OR Diabetic* OR Prediabetic* OR Metabolic Syndrome OR Cardiovascular Disease* OR 
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Disease*) AND (Cost OR Costs OR Economic* OR Expenditure* OR Productivity OR 
Financial burden*)
Abstraction Criteria
Excluded if:
• Title or abstract does NOT contain some indication of ‘cost,’ 
‘comorbidities,’ or ‘cancer.’
• The focus is a specific (single) procedure costs (i.e. cost of surgery X 
among Y cancer patients). [Note that general ‘cancer treatment’ is ok.]
• Cost is a part of cost-effectiveness or comparative-effectiveness studies.
• Non-US. (Patient populations outside the United States.)
• Publication prior to 2000.
• Non-English articles.
• Review articles.
• Non-adult cancer populations.
Included if:
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Key issues
• Cancer survivors with multiple chronic conditions account for greater 
healthcare spending, including out-of-pocket costs, than survivors 
without other chronic conditions.
• Out-of-pocket costs may be a significant financial barrier to care, 
particularly for cancer survivors with multiple comorbidities.
• There is a dearth of published studies that quantified the economic 
burden of multiple chronic conditions among cancer survivors, with the 
economic impact of several common chronic and most costly 
conditions not previously examined.
• No published studies have examined lost productivity resulting from 
comorbidities among cancer survivors.
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Figure 1. 
Flowchart illustrating the study selection process.
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Table 3
Additional per person total medical costs associated with multiple chronic conditions among cancer survivors.
Study Costs measureda Number of comorbidities Total costs
Boltz et al. [25] 1-year costs for thyroid cancer patients (US$ 2009) None Reference
1–2 Comorbidities $13,972*
3+ Comorbidities $37,350*
5-year costs for thyroid cancer patients (US$ 2009) None Reference
1–2 Comorbidities $27,648*
3+ Comorbidities $62,234*
Cohen et al. [26]b Mean spending per person (any cancer) with expenditure (US$ 1997) 1 Comorbidity $7317*
2 Comorbidities $5262*
3+ Comorbidities $12,810*
Forde et al. [28] 7-month (unadjusted median) cost of care for FIGO stage IIIC ovarian 
cancer patients (US$ 2010)
None Reference
1 Comorbidity $1793*
2+ Comorbidities $3949*
7-month (unadjusted median) cost of care for FIGO stage IV ovarian 
cancer patients (US$ 2010)
None Reference
1 Comorbidity $5625
2+ Comorbidities $10,207*
Luo et al. [33] 1-year costs for colon cancer patients (US$ 2000) None Reference
1 Comorbidity $2762*
2 Comorbidities $3095*
3+ Comorbidities $7717*
Hollenbeak et al. [32] 5-year costs for head and neck cancer patients. Marginal effect at 
representative values: 60-year white male with local disease, treated 
with single modality surgery (US$ 1994)c
Increase in WUHNCCI 0–1 $1658*
Increase in WUHNCCI 4–5 $2105*
Increase in WUHNCCI 9–10 $2837*
Hollenbeak et al. [31] 1-year costs for renal cell carcinoma patients (US$ 2005) 1-point increase in CCI $4493*
5-year costs for renal cell carcinoma patients (US$ 2005) 1-point increase in CCI $9505*
Hollenbeak et al. [30] 5-year cost for oral cavity cancer patients (US$ 2005) 0 Comorbidity Reference
1–2 Comorbidities $13,342*
3+ Comorbidities $22,196*
5-year cost for pharyngeal cancer patients (US$ 2005) 0 Comorbidity Reference
1–2 Comorbidities $14,139*
3+ Comorbidities $27,799*
CCI: Charlson Comorbidity Index; WUHNCCI: Washington University Head and Neck Cancer Comorbidity Index; FIGO: International Federation 
of Gynecologists and Obstetricians.
aCosts measured are for all cancer sites unless otherwise noted. Costs are reported as presented in the respective underlying studies.
bCohen et al. is the only paper that does not report on the additional cost of comorbidities. The authors report that estimates for cancer patients with 
zero comorbidities were too small to make reliable national estimates.
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c
The year of cost adjustment could not be ascertained from the study; we assumed it to be the last year of data, 1994.
*
Denotes that the difference was statistically significant at p < .05, per the respective underlying study.
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Table 5
Additional per person medical costs by payer associated with multiple chronic conditions among cancer 
survivors.
Study Costs measureda Number of comorbidities Cost by payer
Out-of-pocket Medicare only
Bernard et al. [24] Annual out-of-pocket expenditures on health care 
(US$ 2008)
Cancer only Reference
Cancer with other chronic 
conditions
$879*
Davidoff et al. [27] 2-year out-of-pocket expenditures on health care 
(US$ 2007)
0–1 Comorbidity Reference
2–4 Comorbidities $1670
5–8 Comorbidities $2133*
9+ Comorbidities $3275*
Luo et al. [33] 1-year costs for colon cancer patients (US$ 2000) None Reference
1 Comorbidity $2781*
2 Comorbidities $3136*
3+ Comorbidities $7796*
aCosts measured are for all cancer sites unless otherwise noted. Costs are reported as presented in the respective underlying studies.
*
Denotes that the difference was statistically significant at p < .05, per the respective underlying study.
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